Senti Biosciences Q4 revenue misses analyst estimates

Senti Biosciences Holdings

27/03/2026 12:11

Overview

US biotech firm's Q4 revenue missed analyst expectations

Adjusted EPS for Q4 was a loss

Company reported positive preliminary clinical data for SENTI-202 and received RMAT designation

Outlook

Company did not provide specific financial guidance for the current or upcoming periods

Result Drivers

PIPELINE ADVANCEMENT - Co cited progress in clinical and translational foundation of pipeline, with SENTI-202 generating positive preliminary clinical data

PLATFORM DEVELOPMENT - Co continued to refine and expand capabilities of its Gene Circuit synthetic biology platform

COST REDUCTIONS - Decrease in general and administrative expenses primarily due to lower external services and supplies costs

Company press release: ID:nGNXbQgbXL

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$22,000
$666,670 (3 Analysts)
Q4 EPS
-$0.53
Q4 Net Income
-$14.47 mln
Q4 Operating Expenses
$18.66 mln
Q4 Operating Income
-$18.64 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Senti Biosciences Inc is $12.50, about 1,318.2% above its March 26 closing price of $0.88

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)